
Dr Vishal A. Patel explores critical scenarios for using cemiplimab in treating high-risk cutaneous squamous cell carcinoma, enhancing patient outcomes through tailored strategies.

Dr Vishal A. Patel explores critical scenarios for using cemiplimab in treating high-risk cutaneous squamous cell carcinoma, enhancing patient outcomes through tailored strategies.

Dr Vishal A. Patel discusses innovative strategies for optimizing cemiplimab in treating high-risk cutaneous squamous cell carcinoma and enhancing patient outcomes.

Dr Patel highlights the groundbreaking C-POST trial results, showcasing cemiplimab's significant impact on disease-free survival in high-risk CSCC patients.

Dr Vishal A. Patel discusses the breakthrough in treating high-risk cutaneous squamous cell carcinoma with FDA-approved cemiplimab, addressing significant patient needs.

Dr Vishal A. Patel discusses the design and patient criteria for the pivotal C-POST trial evaluating adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma.

Vishal A. Patel, MD, discusses the FDA approval of cemiplimab in cutaneous squamous cell carcinoma.